Novartis reports positive breast cancer data for Kisqali

Novartis has announced new clinical trial data that demonstrates the safety and efficacy of its drug Kisqali in the treatment of certain forms of breast cancer.

Findings from the phase III study MONALEESA-2 have demonstrated the benefits offered by Kisqali plus letrozole in treating postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer.

After nearly one year of additional follow-up, Kisqali plus letrozole demonstrated a median progression-free survival rate of 25.3 months, compared to 16 months for letrozole alone.

Patients receiving the Kisqali/letrozole combination were also shown to maintain overall health-related quality of life better than those treated with letrozole alone, while no new safety concerns were identified.

Dr Vas Narasimhan, head of global drug development and chief medical officer at Novartis, said: "We are excited about the potential of Kisqali, and are continuing to evaluate its activity in several phase III trials with multiple hormonal therapy combinations across a broad range of patient populations, including in the adjuvant setting."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.